Efficacy and safety of sintilimab combined with histology-specific chemotherapy in advanced NSCLC: a real-world retrospective study.

Front Pharmacol · 2026 · PMC13294473 · PMID 42367283

Europe PMC DOI

hedged sentence

0.0570

closest p · 1.1× alpha

0.0570

boldest claim

The sentences

showed a trendP = 0.057so close (0.05 < p ≤ 0.1)

However, in patients with ADC, the combination only showed a trend toward improved PFS (median PFS: 11.53 vs. 8.23 months, HR = 0.641, P = 0.057) and did not lead to a significant OS benefit (median OS: 21.87 vs. 30.50 months, HR = 1.043, P = 0.865).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.